Phenobarbital Market Report 2026

Phenobarbital Market Overview

• Phenobarbital market size has reached to $1.54 billion in 2025 • Expected to grow to $1.96 billion in 2030 at a compound annual growth rate (CAGR) of 5% • Growth Driver: Surge In Epilepsy Prevalence Fueling The Growth Of The Phenobarbital Market Due To Rising Seizure Cases Globally • Market Trend: FDA-Approved Phenobarbital Sodium Launches For Neonatal Seizure Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Phenobarbital Market?

Phenobarbital is a long-acting barbiturate medication most commonly used to control and prevent seizures, particularly in the treatment of epilepsy. It is sometimes prescribed as a sedative for anxiety or to manage withdrawal symptoms. It works by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits nerve activity in the brain, resulting in a calming effect on the central nervous system and a reduced risk of seizures. The main types of indications for phenobarbital are epilepsy and neonatal seizures. Epilepsy refers to a neurological disorder characterized by recurrent, unprovoked seizures. It includes various dosage forms such as tablets, capsules, and injectables and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It finds applications in seizure management, anesthesia, sleep disorders, and alcohol withdrawal syndrome, catering to various end users, including hospitals, clinics, research laboratories, and homecare settings.

What Is The Phenobarbital Market Growth Forecast?

The phenobarbital market size is expected to see steady growth in the next few years. It will grow to $1.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to continued demand in low-resource settings, expansion of generic manufacturing, growth in neonatal intensive care units, rising epilepsy diagnosis rates, focus on essential medicines access. Major trends in the forecast period include continued use in epilepsy and neonatal seizure management, increasing availability of generic phenobarbital, growing focus on cost-effective anticonvulsant therapies, expansion of hospital-based seizure management, rising monitoring of long-term drug safety.

Global Phenobarbital Market Segmentation

1) By Indication: Epilepsy, Neonatal Seizures 2) By Dosage Forms: Tablets, Capsules, Injectables 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome 5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings Subsegments: 1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy 2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

What Is The Driver Of The Phenobarbital Market?

The increasing prevalence of epilepsy is expected to propel the growth of the phenobarbital market going forward. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. The increasing prevalence of epilepsy is due to better awareness, as more people are recognizing symptoms and seeking medical diagnosis, leading to higher reported cases. Phenobarbital is useful for epilepsy as it is an anticonvulsant medication that works by slowing down the activity of the brain's neurons, helping to prevent and control seizures. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international public health agency, around 50 million people worldwide were living with epilepsy, reaffirming its position as one of the most common neurological diseases globally. Therefore, the increasing prevalence of epilepsy is expected to propel the growth of the phenobarbital industry.

Key Players In The Global Phenobarbital Market

Major companies operating in the phenobarbital market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Fresenius Kabi AG, Baxter International Inc., Par Pharmaceutical Inc., Harman Finochem Ltd., Manus Aktteva Biopharma LLP, Shandong Xinhua Pharmaceutical Co. Ltd., Alkaloida Chemical Company Zrt., Yashiro Pharmaceutical Co. Ltd., JPN Pharma Pvt. Ltd., Pfizer CentreOne, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd.

Global Phenobarbital Market Trends and Insights

Major companies operating in the phenobarbital market are focusing on developing innovative solutions, such as phenobarbital sodium, to enhance the effectiveness and safety of treatments. Phenobarbital sodium refers to the sodium salt form of phenobarbital, a medication primarily used as an anticonvulsant and sedative. It is commonly prescribed to manage seizures, particularly in conditions such as epilepsy, as well as to treat anxiety and insomnia and sometimes to induce sedation before medical procedures. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S., the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates. This new formulation is benzyl alcohol-free and propylene glycol-free, making it safer for use in newborns. SEZABY received orphan drug designation and is backed by clinical data showing it effectively controls neonatal seizures, addressing a critical unmet need in this vulnerable patient population.

What Are Latest Mergers And Acquisitions In The Phenobarbital Market?

In September 2023, Pharmanovia Limited, a UK-based healthcare lifecycle management company, acquired central nervous system (CNS) portfolio of Sanofi S.A. for an undisclosed amount. Through this acquisition, Pharmanovia aims to strengthen and expand its neurology/CNS franchise by pursuing market growth and product diversification, while utilizing its lifecycle-management expertise to sustain and advance established CNS medicines. Sanofi S.A. is a France-based healthcare company that specializes in the research, development, and commercialization of prescription medicines and vaccines worldwide.

Regional Insights

North America was the largest region in the phenobarbital market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Phenobarbital Market?

The phenobarbital market consists of sales of products including phenobarbital tablets, phenobarbital oral elixir, phenobarbital injectables, veterinary phenobarbital products, and combination medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Phenobarbital Market Report 2026?

The phenobarbital market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the phenobarbital industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.